MP
ZVSAW

Mangrove Partners’s ZyVersa Therapeutics, Inc. Warrants ZVSAW Stock Holding History

Mangrove Partners’s Portfolio ZVSAW Stock Details ZVSAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-149,350
Closed -$1.48M – 566
2022
Q2 		$1.48M Hold
149,350
– – 0.07% 354
2022
Q1 		$1.49M Buy
+149,350
New +$30.2K 0.08% 335

Other funds holding ZVSAW

EFI
EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Mangrove Partners's ZVSAW Position: Q3 2022 in Review

Mangrove Partners sold out of ZyVersa Therapeutics, Inc. Warrants (ZVSAW) in Q3 2022, closing a stake of 149,350 shares — an estimated $1.48M sold.

Mangrove Partners first reported a position in ZVSAW in Q1 2022 and held it in 2 quarters. The position peaked at $1.49M in Q1 2022. 19 funds tracked by Wall St. Rank hold ZVSAW as of Q3 2022.

  • Mangrove Partners reported no remaining ZyVersa Therapeutics, Inc. Warrants position as of Q3 2022 after selling out during the quarter.
  • Mangrove Partners sold 149,350 ZyVersa Therapeutics, Inc. Warrants shares in Q3 2022, an estimated $1.48M.
  • Mangrove Partners first reported a position in ZyVersa Therapeutics, Inc. Warrants in Q1 2022 and held it in 2 quarters.
  • Mangrove Partners's ZyVersa Therapeutics, Inc. Warrants position peaked at $1.49M in Q1 2022.
  • 19 funds tracked by Wall St. Rank held ZyVersa Therapeutics, Inc. Warrants as of Q3 2022.

Based on Mangrove Partners's 13F filing for Q3 2022, filed 14 Nov 2022.